ArticleFrontiers in oncology2026
Situs inversus totalis and lung cancer: a case report of surgical resection after neoadjuvant chemoimmunotherapy for stage IIIB squamous cell carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic potential and mechanisms of rehabilitation interventions in preventing cancer metastasis.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have emerged as a promising therapeutic strategy for lung cancer. This case report describes a patient with situs inversus totalis (SIT) and initially unresectable, advanced lung squamous cell carcinoma (LSCC) who successfully underwent surgical resection following neoadjuvant therapy with pembrolizumab and chemotherapy. The patient was incidentally found to have SIT and a 6.5 × 5.0 cm mass in the right upper lobe (RUL) with hilar and mediastinal lymphadenopathy on a local chest CT scan. PET-CT scan revealed the RUL lesion (approximately 6.6 cm, SUVmax 13.7) and multiple hypermetabolic lymph nodes in the right hilum and station 4R (largest 1.8×1.8 cm, SUVmax 2.5-5.2). EBUS/TBNA was not performed due to limited availability at the initial treating institution. The tumor was deemed unresectable due to its large size (6.6 cm), central location involving the apical segment bronchus, and bulky N2 disease (station 4R, >2 cm), which increased the risk of incomplete resection and recurrence. A CT-guided biopsy confirmed squamous cell carcinoma. The patient was staged as cT3N2M0 (stage IIIB) and received three cycles of neoadjuvant pembrolizumab (200 mg), cisplatin (60 mg), and paclitaxel (270 mg). A repeat PET-CT at our institution showed significant reduction of the tumor (approximately 1.9×1.7 cm, SUVmax 8.9) and mediastinal (stations 3A, 4) and hilar lymph nodes with decreased metabolic activity (SUVmax 2.5). The restaging was ycT1cN1M0 (stage IIA). Following a multidisciplinary team (MDT) discussion, the patient underwent video-assisted thoracoscopic surgery (VATS) right upper lobectomy with mediastinal lymph node dissection. The final pathology confirmed a pathological complete response in the lymph nodes and minimal residual disease in the primary lesion, yielding a postoperative pathological stage of ypT1cN0M0 (stage IA3). Postoperative management included supportive care, infection control, and airway clearance. The patient was discharged on postoperative day 4 and subsequently received adjuvant pembrolizumab monotherapy. This case demonstrates that neoadjuvant chemoimmunotherapy can effectively downstage initially unresectable advanced LSCC, even in a patient with SIT, creating an opportunity for successful surgical intervention and potentially improving outcomes, thereby informing future clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.